We are actively seeking partnerships with regional pharmaceutical companies. This reduces our overall costs as these companies may be able to absorb our clinical trial costs in their respective countries as well as provide an immediate source of revenue. We are also seeking investments from investors within these same countries in order to establish footholds. In the US, Asia and Europe, we have been talking to more and more end-users, including hospitals, insurance companies, institutions and non-profits that have been very supportive of our goal of maximizing patient impact. Many of these organizations—all potential customers—will be far more receptive and more active as we get closer to commercialization.